Insider · CIK 0001230484
Lawrence A Kenyon
Files at OTLK (Outlook Therapeutics, Inc.). First filing Sep 30, 2024, latest Sep 30, 2024.
In brief
Lawrence A Kenyon files SEC Form 4 as CFO and director at OTLK (Outlook Therapeutics, Inc.). Since Sep 30, 2024, Lawrence A Kenyon has reported 1 open-market buy worth $28k and 0 open-market sells worth $0, the latest filed on Sep 30, 2024.
A track record needs three past buys with six months of prices behind them; Lawrence A Kenyon has 0, so none is measured yet.
The newest scored trade: bought $28k of OTLK on Sep 26, 2024, filed Sep 30, 2024, scored 45 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
OTLK: Outlook Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | OTLKbuy Outlook Therapeutics, Inc. | $28k 5,000 shares | +529% | +31% from low-57% from high |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | OTLK Outlook Therapeutics, Inc. | POpen-market purchase Common Stock | +101,010 | - | - | 106,956 | Aug 14, 2026 |
| Aug 14, 2026 | OTLK Outlook Therapeutics, Inc. | POpen-market purchase Warrants (right to buy)derivative | +101,010 | - | - | 101,010 | Aug 14, 2026 |
| Jul 21, 2026 | OTLK Outlook Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +210,078 | $0.00 | $0 | 210,078 | Jul 23, 2026 |
| Sep 26, 2024 | OTLK Outlook Therapeutics, Inc. | POpen-market purchase Common Stock | +5,000 | $5.69 | $28k | 5,946 | Sep 30, 2024 |
| Mar 20, 2024 | OTLK Outlook Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | Mar 22, 2024 |
Questions about Lawrence A Kenyon
Answered from the filings on this page, as of the latest one.
Is Lawrence A Kenyon buying or selling?
Not in the last 12 months. Lawrence A Kenyon's latest open-market trade on SEC Form 4 was bought $28k of OTLK on Sep 26, 2024.
How did Lawrence A Kenyon's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Lawrence A Kenyon has 0.
Where does Lawrence A Kenyon file Form 4?
Lawrence A Kenyon has filed Form 4 at OTLK (Outlook Therapeutics, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.